Compare D R Horton Inc (DHI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Regeneron Pharmaceuticals Inc — how do they compare? D R Horton Inc trades at $150.79 (market cap $41.02B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2× D R Horton Inc's market cap, and D R Horton Inc pays the higher dividend (1.23%). Which is the better fit depends on your goals.
| DHI | REGN | |
|---|---|---|
Market Cap | $41.02B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $812.27 |
52-Week Low | $132.53 | $555.51 |
Enterprise Value | $46.13B | $77.90B |
Dividend Yield | 1.23% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $151.08, up 3.47% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance amid persistent affordability pressures. Valuation metrics appear reasonable with a P/E of 14.4 and P/S of 1.32, while profitability remains solid with a net income margin of 9.15%.
The outlook is mixed: strong execution and cash returns provide support, but weaker demand and margin pressure pose headwinds. Investment opportunity lies in disciplined inventory management and shareholder returns, while risks include elevated mortgage rates and competitive threats from disruptors like Boxabl. Analyst sentiment is balanced with 45% buy ratings.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
